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widespread popularity. From the perspective of users, it is
more convenient than the pill or coitus-dependent meth-
ods: Whereas the pill needs to be taken every day and con-
doms need to be used at each act of intercourse to be effec-
tive, injections of DMPA—the main injectable in use—are
needed only every three months. Also, unlike many estro-
gen-containing contraceptive pills, progestin-only injecta-
bles are appropriate for lactating women, so they can be
used earlier in the postpartum period.2 Moreover, the in-
jectable can be used discreetly by women who do not wish
their partners to know that they are practicing contracep-
tion.3,4 And for women who are not yet ready for a perma-
nent method, the injectable may be an attractive alternative
to the IUD or implant. From the perspective of busy
providers, injectables may offer advantages over long-acting
reversible methods, such as implants or the IUD, which re-
quire a pelvic exam as well as special skills for insertion or
removal;5 injectables can be administered by doctors and
nurses, and also by providers with less medical education
and medical training, such as community health workers.6
The introduction of the injectable could result in a net in-
crease in contraceptive use. However, adoption of the in-
jectable could replace use of more effective, less expensive
long-acting and permanent methods, especially among
women who wish to longer delay or permanently avoid fu-
ture births.7 Such a substitution could be so great that a sin-
gle method might dominate a country’s method mix, re-
gardless of the age or fertility intentions of contraceptive
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CONTEXT: Although the introduction of a new method is generally hailed as a boon to contraceptive prevalence, up-
take of new methods can reduce the use of existing methods. It is important to examine changing patterns of contra-
ceptive use and method mix after the introduction of new methods.
METHODS: Demographic and Health Survey data from 13 countries were used to analyze changes in method use and
method mix after the introduction of the injectable in the early 1990s. Subgroup analyses were conducted among
married women who reported wanting more children, but not in the next two years (spacers), and those who reported
wanting no more children (limiters).
RESULTS:Modern method use and injectable use rose for each study country. Increases in modern method use exceed-
ed those in injectable use in all but three countries. Injectable use rose among spacers, as well as among limiters of all
ages, particularly those younger than 35. In general, the increase in injectable use was partially offset by declines in use
of other methods, especially long-acting or permanent methods.
CONCLUSION: Family planning programs could face higher costs and women could experience more unintended
pregnancies if limiters use injectables for long periods, rather than changing to longer acting and permanent meth-
ods, which provide greater contraceptive efficacy at lower cost, when they are sure they want no more children.






The introduction of a new contraceptive method can affect
patterns of contraceptive behavior, including method
choice, which in turn can affect method mix and contra-
ceptive prevalence. For example, a new method might at-
tract women who otherwise would not practice contra-
ception, leading to an increase in overall use. According to
a study by Jain of the relationship between method avail-
ability and contraceptive prevalence in 72 countries in
1982, the widespread introduction of a new contraceptive
method could increase total contraceptive prevalence by
as much as 12 percentage points.1 However, a new con-
traceptive method could also draw current users away
from other available methods. This possibility is a concern
from a public health and program perspective if the new
method replaces existing methods that are more effective,
have higher continuation rates or are less expensive. How
much a new method adds to total use or substitutes for
other methods has not been well documented.2
Use of injectable hormonal contraceptives has risen
rapidly in many countries.3 The injectable’s widespread in-
troduction into family planning programs worldwide fol-
lowed the approval of Depo Provera (depot medroxy-
 progesterone acetate; DMPA) by the United States Food
and Drug Administration in 1992. From 1995 to 2005, the
estimated number of injectable users more than doubled,
to more than 32 million; by 2015, as many as 40 million
women are expected to be using the method. 
The injectable has many benefits, which help explain its
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limiters in the 13 study countries over the study period
(range, 33–39 years). Older age may be a proxy for
strength of motivation to end childbearing. Furthermore,
there is less time for an older limiter to change her desires
before she becomes infecund.
Changes in contraceptive use were categorized as posi-
tive or negative if the value of the contraceptive use vari-
able increased or decreased by more than one percentage
point. In this way, spurious or small changes in use of con-
traceptives were not considered. We considered the in-
jectable to have dominated changes in modern method
use if its use accounted for 50% or more of the change in
use of all modern methods.
RESULTS
Overall Trends in Contraceptive Use
Overall, the prevalence rates for the injectable and for any
modern method ranged widely by country and over time
(Table 1, page 204). In each country, injectable use and
modern method use increased over the study period. 
At baseline, injectable use was low in most countries;
four countries—Bolivia, Egypt, Tanzania and Zambia—had
initial injectable prevalence rates of no more than 1%. Ex-
ceptions included Indonesia, Kenya and Namibia, which
had baseline injectable prevalence of more than 5%. At
endline, injectable prevalence was lower than 10% in only
four countries. 
Overall modern method use also varied substantially.
The lowest baseline rates were in Haiti, Malawi, Tanzania
and Zambia (7–13%), whereas the highest were in Egypt,
Indonesia, Nicaragua and Zimbabwe (42–57%). By end-
line, only three countries had modern method prevalence
lower than 30%.
The importance of the injectable in countries’ method
mix varied greatly. For the nine countries in which at least
10% of women relied on the injectable, the method ac-
counted for at least 40% of modern method use in five of
those—Haiti, Indonesia, Kenya, Malawi and Namibia—at
the time of the last survey (not shown); in the other four,
the proportions ranged from 17% to 23%.
Given our criteria for choosing countries, it is not sur-
prising that the increase in injectable use from baseline to
endline was substantial in most countries (Figure 1, page
205). The increase in injectable use varied from a low of
five percentage points in Nepal to a high of 20 points in In-
donesia. Modern method use increased by as little as five
points in Kenya to as much as 27 points in Namibia. Nine
countries experienced an increase in modern method use
of at least 12 points, the amount predicted by Jain,1 and
two others had an increase close to that. Increases in mod-
ern method use exceeded increases in injectable use in all
but three countries: Indonesia and Kenya experienced
greater increases in injectable use than in modern method
use, while in Nicaragua, injectable use and modern
method use increased by the same amount. In 10 coun-
tries, the increase in injectable use accounted for at least
half of the change in modern method use.
users.8 If programs reacted to this situation by stocking only
the most popular methods, women’s ability to choose from
a range of effective methods could be greatly diminished.
In this article, we document recent global trends in use of
the injectable and other modern methods. Because we hy-
pothesize that trends in contraceptive use could be affected
by changing fertility preferences and motivations, we con-
sider women’s desires for the timing and spacing of addi-
tional children—building on the work of Seiber et al.9 We
also build on the study by Jain,1 by determining whether the
potential gains that he estimated in contraceptive prevalence
have been realized by the introduction of the injectable. Fur-
ther, we examine whether the use of other methods has de-
clined as injectable use has risen, and if so, which methods
have seen the greatest changes in use.
METHODS
Data for this analysis were drawn from Demographic and
Health Surveys (DHS). We included countries that had
had two or more surveys since the introduction of the in-
jectable in the early 1990s, modern contraceptive preva-
lence of at least 20% in the most recent survey and at least
a five-percentage-point increase in injectable use between
the early 1990s and the most recent survey. These criteria
were selected to focus the analysis on the countries on
which the injectable might have had the greatest impact in
terms of contraceptive use outcomes. Thirteen countries,
representing a variety of world regions, met the selection
criteria: Bolivia, Egypt, Haiti, Indonesia, Kenya, Malawi,
Namibia, Nepal, Nicaragua, Peru, Tanzania, Zambia and
Zimbabwe. For the purposes of this study, we refer to the
first survey in each country within the study period as the
baseline and the most recent survey as the endline.
Because some surveys did not interview single women,
our analysis was restricted to women in union, to make
comparisons across countries easier. All analyses were con-
ducted individually by country and survey year to appro-
priately account for survey weights. 
Descriptive analyses were used to examine trends in
contraceptive use and method mix. Method mix was re-
stricted to modern methods, including injectables, other
short-acting hormonal methods (e.g., the pill), barrier
methods, the Standard Days method and the lactational
amenorrhea method, as well as such permanent or long-
acting methods as male and female sterilization, the IUD
and the implant.
We categorized potential contraceptive users as either
“spacers” (those who reported wanting more children, but
not for at least two years) or “limiters” (those who report-
ed not wanting any more children); women not interested
in spacing or limiting their childbearing were excluded. In
some analyses, we stratified limiters by age, because
method choice may be affected by the strength of women’s
motivation to avoid having additional children, which may
vary by age and the closely correlated variable, number of
living children. We used age 35 to divide younger and
older limiters, because it was the approximate mean age of
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Contraceptive Use Patterns by Subgroup
The increase in injectable use in all countries except Zim-
babwe was highest among spacers or younger limiters
rather than among older limiters (Table 2, page 206); in six
countries, the largest increases occurred among spacers
(from eight percentage points in Nepal to 32 points in
Malawi) and in six countries, among younger limiters (from
11 points in Nepal to 33 points in Indonesia). Even so, in-
jectable use rose sharply among older limiters, from five
points in Bolivia to 21 points in Indonesia. We found no
TABLE 1. Percentage of women in union using the injectable and percentage using any modern method, by  Demographic and
Health Survey year, according to country and subgroup 
Country 1991–1993 1994–1996 1997–1999 2000–2003 2004–2007
DMPA Any DMPA Any DMPA Any DMPA Any DMPA Any
Bolivia u u u u 1 25 8 35 u u
Spacers u u u u 2 33 9 41 u u
Young limiters u u u u 2 31 13 43 u u
Older limiters u u u u 1 35 6 42 u u
Egypt 1 45 2 46 u u 6 54 7 57
Spacers <1 48 2 53 u u 5 70 5 69
Young limiters <1 71 5 72 u u 11 86 13 86
Older limiters 1 75 4 75 u u 10 81 11 87
Haiti u u 3 13 u u 12 23 11 25
Spacers u u 5 18 u u 15 29 14 34
Young limiters u u 6 21 u u 25 40 25 40
Older limiters u u 2 22 u u 11 29 10 31
Indonesia 12 47 15 52 21 55 28 57 32 57
Spacers 22 65 28 74 37 78 48 80 53 80
Young limiters 21 80 26 82 36 84 46 84 54 85
Older limiters 11 76 13 78 19 78 27 79 32 80
Kenya 7 27 u u 12 32 14 32 u u
Spacers 6 23 u u 13 32 20 36 u u
Young limiters 17 55 u u 28 59 29 54 u u
Older limiters 11 50 u u 18 61 18 59 u u
Malawi 2 7 u u u u 16 26 18 28
Spacers 1 10 u u u u 28 37 33 44
Young limiters 2 18 u u u u 30 44 31 50
Older limiters 8 24 u u u u 20 46 18 63
Namibia 8 26 u u u u 19 43 22 53
Spacers 13 33 u u u u 29 53 29 64
Young limiters 25 70 u u u u 36 67 40 73
Older limiters 12 65 u u u u 18 66 19 73
Nepal u u 5 26 u u 8 35 10 44
Spacers u u 4 10 u u 9 19 12 29
Young limiters u u 11 52 u u 16 59 16 65
Older limiters u u 6 60 u u 11 66 12 71
Nicaragua u u u u 5 57 14 66 u u
Spacers u u u u 10 62 25 74 u u
Young limiters u u u u 7 78 20 81 u u
Older limiters u u u u 3 81 7 81 u u
Peru 2 33 8 41 u u 15 50 11 47
Spacers 3 37 11 47 u u 22 57 15 54
Young limiters 3 39 14 53 u u 25 65 19 54
Older limiters 2 43 4 50 u u 8 61 9 60
Tanzania <1 7 5 13 6 17 u u 8 20
Spacers <1 13 9 25 13 34 u u 16 35
Young limiters 3 20 12 37 13 41 u u 22 48
Older limiters 2 23 11 35 13 35 u u 15 44
Zambia <1 9 1 14 u u 5 25 9 33
Spacers <1 15 2 24 u u 5 39 15 48
Young limiters <1 25 3 37 u u 12 48 13 52
Older limiters <1 26 2 28 u u 7 36 9 43
Zimbabwe u u 3 42 8 50 u u 10 58
Spacers u u 3 63 8 74 u u 10 79
Young limiters u u 8 75 18 80 u u 16 82
Older limiters u u 7 57 16 67 u u 17 76
Notes:DMPA=the injectable (depot medroxyprogesterone acetate).  Spacers were women who reported wanting more children, but not in the next two years. Lim-
iters were women who reported not wanting any more children. Younger limiters were those younger than 35; older limiters were 35 or older. u=unavailable be-
cause no survey was done during time period. 
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permanent methods. In contrast, use of short-acting meth-
ods other than the injectable increased among at least one
group of limiters in 10 of the 13 study countries. Thus,
even though limiters, by definition, want no more chil-
dren, an increasing proportion of them used short-acting
methods, especially injectables.
Among the countries in which use of long-acting and per-
manent methods decreased among some limiters, no one
method dominated the decrease: Six countries experienced
declines (of more than one percentage point) in sterilization
and six experienced declines in IUD use (Table 4, page
207). The largest declines in sterilization occurred in Namib-
ia and Zambia (nine and six points, respectively), with
smaller declines in Haiti, Kenya, Nicaragua and Zimbabwe
(3–5 points). Indonesia had the largest decrease in IUD
prevalence (16 points), but IUD use also decreased in Bo-
livia, Kenya, Namibia, Nicaragua and Peru (2–8 points). For
the two countries that had large increases in long-acting and
permanent method prevalence, the methods that dominat-
ed that change differed: Egypt experienced an 11-point in-
crease in IUD use, whereas Malawi experienced a 10-point
increase in reliance on sterilization.
Sample Cases: Indonesia and Malawi
Two case studies—Indonesia and Malawi—illustrate our find-
ing that countries can experience increases in injectable use
with different changes in overall contraceptive use and
 evidence in most countries of a shift over time in the pro-
portion of women overall classified as spacers or limiters
that could confound any trends seen among these spacing
groups (not shown); the exceptions were Malawi, Namibia
and Zambia—all of which had increases in the proportion of
all women classified as spacers or limiters, as well as an in-
crease in the total classified in these groups.
When we examined changes in injectable use relative to
changes in use of any modern method, no consistent pat-
tern emerged (Table 3, page 207). The injectable was the
dominant method—that is, the change in injectable use ac-
counted for at least half of the change in all modern con-
traceptive use—in 10 countries (not shown). However,
there was no pattern in the number of countries in which
the injectable dominated the change in modern method
use across subgroups: By adding the first three columns of
each row, we can see that the injectable dominated the
change among spacers in nine countries, among younger
limiters in 11 countries and among older limiters in 10
countries. With a more stringent criterion for dominance—
the change in injectable use exceeded or equaled the
change in modern method use (first two columns only)—
again there is no apparent pattern in the number of coun-
tries by subgroup (four, eight and four, respectively). What
does stand out is that of the 16 country combinations of
dominance and desired pregnancy spacing (e.g., Indone-
sia/spacers), there is clearly clustering, with six of the com-
binations accounted for by Indonesia and Nicaragua, and
two each by Bolivia, Haiti, Kenya and Namibia. These find-
ings indicate that if injectables play a dominant role in one
subgroup in a given country, they usually do so in at least
one other group. Thus, injectables apparently play a fairly
consistent role in affecting method use across all user sub-
groups, rather than having a different impact in the vari-
ous spacing groups and, in general, have become the most
commonly used method in each subgroup.
Changes in the Use of Other Methods
We next explore changes in the use of other contraceptive
methods (Table 2). Among spacers, the proportion relying
on short-acting methods other than the injectable increased
in all countries except Indonesia and Kenya, and in four
countries, the proportion using short-acting methods in-
creased more than the proportion using injectables. In con-
trast, the proportion of spacers relying on long-acting and
permanent methods increased in just one country (Egypt),
decreased substantially in three countries (Indonesia,
Nicaragua and Peru) and either remained stable or showed
small declines in the remainder. Thus, it seems that since the
introduction of the injectable, the proportion of spacers may
have shifted from using long-acting methods to using in-
jectables and other short-acting methods.
In general, the proportion of limiters relying on long-
acting or permanent methods also declined. In only four
countries (Egypt, Malawi, Nepal and Tanzania) was there
an increase over the study period in the proportion of lim-
iters (younger, older or both) relying on long-acting and


















FIGURE 1. Percentage point change between baseline and endline surveys in the pro-
portion of currently married women using the injectable or any modern method, by
country
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method mix. The two countries experienced the two largest
changes in injectable use overall and in five of the six sub-
groups (excluding older limiters for Malawi), yet the pattern
of injectable dominance varied. In Indonesia, the increase
in modern method use was smaller than the increase in in-
jectable use for all three subgroups. On the other hand, in
Malawi, injectables dominated the change in modern
method mix among spacers and younger limiters only, but
by a smaller proportion than in Indonesia. 
The differences in the changes in method use between
the two countries are particularly striking with respect to
long-acting and permanent methods. In Indonesia, use of
such methods decreased among all three contraceptive
subgroups: eleven percentage points among spacers, and
23 points and 16 points among younger and older lim-
iters, respectively (Table 2). In Malawi, however, use of
long-acting and permanent methods did not decrease in
any subgroup, and in fact increased among both younger
and older limiters (two points and 22 points, respective-
ly). When we looked at changes in use of specific long-
 acting and permanent methods use among limiters,
Malawi’s biggest change was a 10-point increase in steril-
ization use, whereas the biggest change in Indonesia was
a 16-point decrease in IUD use (Table 4). 
DISCUSSION
Nine of the countries included in this study experienced
an increase in modern method use of at least 12 percent-
age points following the widespread introduction of the in-
jectable—giving support to Jain’s predictions;1 two other
countries had increases almost that large. Other countries,
however, experienced smaller changes in modern method
use, especially among particular subgroups of users. In the
vast majority of cases, the change in method mix was dom-
inated by increasing use of injectables.
It is, of course, the overall changes in method mix,
rather than changes in the use of a single method, that are
of critical importance to setting policy and program prior-
ities in low-resource settings,9 and understanding changes
in method mix requires analysis of subgroups of spacers
and limiters. Our analysis demonstrates that long-acting
and permanent method use decreased in many countries—
 particularly among limiters—as injectable use increased.
Changes in the method mix used by limiters were similar
to those for spacers, whose reliance on short-acting meth-
ods, including the injectable, increased over time. How-
ever, many spacers may have chosen to rely on the in-
jectable and other short-acting methods because the IUD
may have been the only reversible long-acting method
available. 
Younger limiters who are not yet ready to make a final
decision to not have another child may face method
 choices as restricted as women who want to delay their
next birth. Older limiters who feel certain that they do not
want more children could, perhaps, more comfortably se-
lect IUDs or sterilization; nevertheless, adoption of long-
 acting and permanent methods in this group declined in
most countries. This decline could be a concern from a
programmatic perspective, if it were associated with high-
er contraceptive discontinuation rates or a higher inci-
dence of unintended pregnancy.
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TABLE 2. Percentage of women in union using contraceptive methods, by type of
method used at first and last survey, according to country and subgroup
Country (survey period) Injectable Other Long-acting/
short-acting permanent
First Last First Last First Last
Bolivia (1998–2003)
Spacers 2 9 13 14 18 17
Younger limiters 2 13 10 13 20 16
Older limiters 1 6 4 9 30 27
Egypt (1992–2005)
Spacers <1 5 13 16 35 48
Younger limiters <1 13 23 15 45 55
Older limiters 1 11 26 15 43 58
Haiti (1994–2006)
Spacers 5 14 10 19 2 1
Younger limiters 6 25 9 11 7 4
Older limiters 2 10 7 10 14 12
Indonesia (1991–1997)
Spacers 22 53 26 20 18 7
Younger limiters 21 54 24 20 34 11
Older limiters 11 32 22 22 43 27
Kenya (1993–2003)
Spacers 6 20 14 12 4 4
Younger limiters 17 29 23 17 15 9
Older limiters 11 18 9 13 30 28
Malawi (1992–2004)
Spacers 1 33 8 11 1 1
Younger limiters 2 31 8 5 8 10
Older limiters 8 18 5 3 11 33
Namibia (1992–2007)
Spacers 13 29 17 33 3 1
Younger limiters 25 40 22 25 23 8
Older limiters 12 19 11 19 42 35
Nepal (1996–2006)
Spacers 4 12 5 16 1 1
Younger limiters 11 16 7 14 35 35
Older limiters 6 12 4 6 50 54
Nicaragua (1997–2001)
Spacers 10 25 33 38 19 11
Younger limiters 7 20 21 24 50 38
Older limiters 3 7 11 11 68 63
Peru (1992–2008)
Spacers 3 15 14 28 20 11
Younger limiters 3 19 13 18 23 16
Older limiters 2 9 9 17 33 34
Tanzania (1992–2004)
Spacers <1 16 11 17 1 2
Younger limiters 3 22 11 18 7 9
Older limiters 2 15 6 10 15 19
Zambia (1992–2007)
Spacers <1 15 14 34 1 <1
Younger limiters <1 13 18 37 8 3
Older limiters <1 9 9 24 17 11
Zimbabwe (1994–2006)
Spacer 3 10 59 67 1 2
Younger limiters 8 16 60 61 8 5
Older limiters 7 17 37 46 13 13
Notes: Spacers were women who reported wanting more children, but not in the next two years. Limiters were
women who  reported not wanting any more children. Younger limiters were those younger than 35; older
 limiters were 35 or older.
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CONCLUSIONS
From a program perspective, more emphasis on long- acting
and permanent method provision might lead to greater pre-
vention of unintended pregnancy and lower costs; howev-
er, such emphasis should not be at the expense of women’s
method choices to meet their goals for both spacing and lim-
iting. Ideally, women would progress from shorter- to
longer-acting methods, and finally to a permanent method
when they were sure that they would not want more chil-
dren. As a result, unplanned pregnancies would decrease
and the costs of providing contraception would decline. In-
stead, according to our analysis, the opposite may have oc-
curred in some of our study countries: Costly short-acting
methods (especially the injectable) have become more wide-
ly used, regardless of age and fertility intention.
Despite dramatic increases in family planning, about
one in six married women continue to have an unmet
need. Given the decrease in donor funds for contraception
as funds have been reallocated to HIV and AIDS pro-
Differences in method mix trends have cost implications
for family planning programs. Our results for Indonesia and
Malawi illustrate this point. In Indonesia, the proportion of
limiters relying on injectables rose as the proportion using
long-acting and permanent methods declined. Meanwhile,
in Malawi, the proportion of limiters relying on long-acting
methods and the proportion using injectables both in-
creased. All else being equal, in areas where limiters tend to
adopt relatively inexpensive, long-acting or permanent
methods at fairly young ages, continuation rates would be
higher and contraceptive costs would be lower than in areas
where such limiters rely on the injectable or other more-
 expensive, short-acting methods. 
Increasing availability of contraceptive implants or de-
velopment of new or less-expensive options, particularly in
long-acting reversible methods, would widen contraceptive
choices and could reduce contraceptive costs for country
programs. Although many implants are costly, perhaps even
more costly than injectables if used for a short period of
time, a low-cost implant such as the one recently registered
in Kenya could prove to be a more cost-effective alternative
to injectables, even if used for short periods of time.10
Although the importance of the injectable in the
method mix raises potential programmatic concerns, es-
pecially for limiters, it is important to recognize the posi-
tive impacts of the introduction of the method. Overall
contraceptive use increased in all 13 countries we exam-
ined, and increased by at least 10 percentage points in 11
of those. The injectable, by increasing women’s choices
and providing an alternative to methods that are coitus-
 dependent or must be taken daily, likely contributed to
this gain—particularly in countries that had very low con-
traceptive use only 10–15 years ago. 
Limitations
This study has several limitations. Although our results
 indicate that long-acting and permanent method use
 declined in most countries after the introduction of the
 injectable, we cannot definitively conclude that the popu-
larity of the new method was the cause. The decrease could
be explained by a host of other program and policy con-
cerns that could include the shifting of funds from family
planning to other public health priorities or increased at-
tention to emerging family planning priorities, such as
method provision for youth, lengthened interval between
marriage and a first birth for newlyweds or the use of bar-
rier methods for dual protection against pregnancy and STI
prevention for individuals with risky sexual behavior—all
of which are unlikely. 
An additional limitation was that all analyses were re-
stricted to the years in which data were collected in each
country, and the length of time between the first and last
survey varied widely across countries. Further, it is im-
possible to determine whether the time period for which
data were available best captures the period in which in-
jectable use increased. In fact, the trends described in this
paper may be in flux.
TABLE 3. Distribution of countries, by comparisons between percentage point
changes in injectable use and in any modern method use, according to subgroup
Category DMPA dominates DMPA does 
not dominate
DMPA/any DMPA/any DMPA/any DMPA/any 
>1.0 =1.0 =0.5–0.99 <0.5
Spacers 2 (Indonesia, 2 (Bolivia, 5 (Haiti, Malawi, 4 (Egypt, Nepal,
Nicaragua) Kenya) Namibia, Peru, Zambia, 
Tanzania) Zimbabwe)
Younger limiters 4 (Indonesia,  4 (Bolivia, 3 (Egypt, Malawi, 2 (Nepal, 
Kenya, Haiti, Peru, Tanzania) Zambia)
Namibia, Zimbabwe)
icaragua)
Older limiters 2 (Indonesia, 2 (Haiti, 6 (Bolivia, Egypt, 3 (Malawi, Peru,
Nicaragua) Namibia) Kenya, Nepal, Zambia)
Tanzania, Zimbabwe)
Total 8 8 14 9
Notes:DMPA=the injectable (depot medroxyprogesterone acetate). The injectable was considered to have dom-
inated a country’s change in modern method use if its use accounted for at least 50% of the change in use of any
modern methods. Spacers were women who reported wanting more children, but not in the next two years.
Limiters were women who reported not wanting any more children. Younger limiters were those younger than
35; older limiters were 35 or older.
TABLE 4. Change between first and last surveys in the
 percentage of limiters using specific long-acting and
 permanent methods
Country Sterilization IUD Implant
Bolivia –1 –3 0
Egypt 0 11 1
Haiti –3 0 1
Indonesia –1 –16 –1
Kenya –3 –3 3
Malawi 10 –1 1
Namibia –9 –2 0
Nepal 1 1 0
Nicaragua –5 –3 0
Peru 6 –8 0
Tanzania 3 –1 1
Zambia –6 –1 1
Zimbabwe –3 –1 2
Note: Limiters were women who reported not wanting any more children.
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grams,11 countries may need to emphasize a cost-effective
method mix. A combination of interventions may be need-
ed to foster demand and to promote and provide longer-
acting and permanent methods to women for whom they
are appropriate. Strategies for how such changes can be
made and sustained by family planning programs need to
be developed and tested as part of the continuing contra-
ceptive research agenda.
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RESUMEN
Contexto: Aunque la introducción de un nuevo método se re-
cibe generalmente como algo muy positivo para la prevalencia
del uso de anticonceptivos, la aceptación de un nuevo método
puede reducir el uso de los métodos existentes. Es importante
examinar cómo un nuevo método cambia los patrones del uso
y la combinación de métodos usados. 
Métodos: Se usaron datos de las Encuestas Demográficas y de
Salud de 13 países, desde los años noventa hasta fechas re-
cientes, para analizar cambios en el uso de métodos y la com-
binación de métodos posteriores a la introducción de los in-
yectables a principios de los años noventa. Se realizó análisis
de mujeres casadas según sus preferencias de fecundidad: las
que deseaban tener más hijos pero no en los próximos dos años
(buscaban espaciar sus hijos); y las que no deseaban tener más
hijos (buscaban limitar el número de hijos). 
Resultados: El uso de métodos modernos, y del método mo-
derno individual del inyectable, aumentó en cada país del es-
tudio. Los aumentos en el uso de métodos modernos en total
excedieron los aumentos en el uso del inyectable en todos los
países con excepción de tres. El uso del inyectable aumentó
entre las mujeres de todas las edades que querían espaciar los
nacimientos; así como entre todas las que querían dejar de pro-
crear, pero especialmente en las menores de 35 años de estas
últimas. En general, el aumento en el uso del inyectable se com-
pensó parcialmente por disminuciones en el uso de otros mé-
todos, especialmente los de larga duración o permanentes. 
Conclusión: Los programas de planificación familiar podrí-
an enfrentar costos mayores, y las mujeres podrían tener más
embarazos no planeados, si las que quieren dejar de procrear
usan los inyectables por períodos largos en lugar de cambiar a
métodos de larga duración y métodos permanentes. Es decir,
cuando las mujeres están seguras de que no desean más hijos,
los métodos permanentes y los de larga duración proporcionan
una mayor eficacia anticonceptiva a menor costo.
RÉSUMÉ
Contexte: Bien que l’introduction d’une nouvelle méthode soit
généralement saluée comme une aubaine pour la prévalence
contraceptive, l’adoption de nouvelles méthodes peut réduire
la pratique de celles existantes. Il importe d’examiner les ten-
dances changeantes de la pratique contraceptive et de l’éventail
de méthodes après l’introduction de nouveaux choix.
Méthodes: Les données d’EDS de 13 pays ont servi à analyser
les changements de pratique et d’éventail de méthodes après
l’introduction de l’injectable au début des années 1990. Des
analyses de sous-groupes ont été menées parmi les femmes ma-
riées ayant déclaré désirer avoir encore des enfants mais pas du-
rant les deux prochaines années (désir d’espacement) et celles
ayant déclaré ne plus vouloir d’enfants (désir de limitation).
Résultats: La pratique des méthodes modernes et celle de l’in-
jectable ont augmenté dans chaque pays soumis à l’étude. La
hausse de la pratique des méthodes modernes dépasse celle du
choix de l’injectable dans tous les pays sauf trois. La pratique
de l’injectable a augmenté parmi les femmes désireuses d’es-
pacer leurs grossesses tout comme parmi celles désireuses de les
limiter à tous âges, en particulier avant l’âge de 35 ans. En gé-
néral, la hausse de la pratique de l’injectable est partiellement
compensée par la baisse enregistrée au niveau d’autres mé-
thodes, de longue durée ou permanentes surtout.
Conclusion: Les programmes de planification familiale pour-
raient se trouver confrontés à des coûts supérieurs et les femmes
à de plus grands nombres de grossesses non planifiées si celles
désireuses de limiter leurs naissances recourent aux injectables
à long terme, plutôt que de passer aux méthodes longue durée
ou permanentes qui leur assureraient une plus grande efficaci-
té contraceptive à moindre coût lorsqu’elles sont sûres de ne
plus vouloir d’enfants. 
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